Profiling of the Human Natural Killer Cell Receptor-Ligand Repertoire.
Journal
Journal of visualized experiments : JoVE
ISSN: 1940-087X
Titre abrégé: J Vis Exp
Pays: United States
ID NLM: 101313252
Informations de publication
Date de publication:
19 11 2020
19 11 2020
Historique:
entrez:
7
12
2020
pubmed:
8
12
2020
medline:
29
12
2020
Statut:
epublish
Résumé
Natural killer (NK) cells are among the first responders to viral infections. The ability of NK cells to rapidly recognize and kill virally infected cells is regulated by their expression of germline-encoded inhibitory and activating receptors. The engagement of these receptors by their cognate ligands on target cells determines whether the intercellular interaction will result in NK cell killing. This protocol details the design and optimization of two complementary mass cytometry (CyTOF) panels. One panel was designed to phenotype NK cells based on receptor expression. The other panel was designed to interrogate expression of known ligands for NK cell receptors on several immune cell subsets. Together, these two panels allow for the profiling of the human NK cell receptor-ligand repertoire. Furthermore, this protocol also details the process by which we stain samples for CyTOF. This process has been optimized for improved reproducibility and standardization. An advantage of CyTOF is its ability to measure over 40 markers in each panel, with minimal signal overlap, allowing researchers to capture the breadth of the NK cell receptor-ligand repertoire. Palladium barcoding also reduces inter-sample variation, as well as consumption of reagents, making it easier to stain samples with each panel in parallel. Limitations of this protocol include the relatively low throughput of CyTOF and the inability to recover cells after analysis. These panels were designed for the analysis of clinical samples from patients suffering from acute and chronic viral infections, including dengue virus, human immunodeficiency virus (HIV), and influenza. However, they can be utilized in any setting to investigate the human NK cell receptor-ligand repertoire. Importantly, these methods can be applied broadly to the design and execution of future CyTOF panels.
Identifiants
pubmed: 33283785
doi: 10.3791/61912
pmc: PMC7935321
mid: NIHMS1668594
doi:
Substances chimiques
Antibodies
0
Intercalating Agents
0
Ligands
0
Receptors, Natural Killer Cell
0
DNA
9007-49-2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Video-Audio Media
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : U19 AI057229
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068634
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI131798
Pays : United States
Organisme : NIDA NIH HHS
ID : DP1 DA046089
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI068636
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI135287
Pays : United States
Organisme : NIAID NIH HHS
ID : K08 AI138640
Pays : United States
Organisme : NCATS NIH HHS
ID : TL1 TR001084
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007502
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007290
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI068634
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068636
Pays : United States
Références
Front Cell Infect Microbiol. 2019 Jul 23;9:268
pubmed: 31396492
Front Immunol. 2019 Nov 05;10:2584
pubmed: 31749810
Immunology. 2017 Mar;150(3):248-264
pubmed: 27779741
Cell Rep. 2019 Nov 19;29(8):2284-2294.e4
pubmed: 31747601
Cytometry A. 2017 Oct;91(10):997-1000
pubmed: 28715616
PLoS One. 2020 Sep 1;15(9):e0238347
pubmed: 32870938
Science. 2011 May 6;332(6030):687-96
pubmed: 21551058
J Immunol. 2015 Feb 15;194(4):2022-31
pubmed: 25609839
Front Immunol. 2019 May 03;10:982
pubmed: 31130961
AIDS. 2020 May 1;34(6):801-813
pubmed: 32028328
Nat Immunol. 2008 May;9(5):503-10
pubmed: 18425107
Cytometry A. 2015 May;87(5):380-2
pubmed: 25904393
Cytometry A. 2012 Jun;81(6):447-9
pubmed: 22411905
Blood Adv. 2020 Sep 8;4(17):4244-4255
pubmed: 32898247
Nat Rev Drug Discov. 2020 Mar;19(3):200-218
pubmed: 31907401
J Exp Med. 2019 Jun 3;216(6):1255-1267
pubmed: 31040184
J Leukoc Biol. 2019 May;105(5):1055-1073
pubmed: 30794328
Proc Natl Acad Sci U S A. 2017 Nov 7;114(45):E9626-E9634
pubmed: 29078283
Cytometry A. 2012 Jun;81(6):467-75
pubmed: 22577098
Blood. 2013 Apr 4;121(14):2678-88
pubmed: 23325834
Cytometry A. 2017 Jan;91(1):39-47
pubmed: 27632576
Methods Mol Biol. 2015;1343:81-95
pubmed: 26420710
Front Immunol. 2020 Apr 24;11:714
pubmed: 32391016
Front Immunol. 2018 Apr 09;9:486
pubmed: 29686665
Cytometry A. 2017 Jan;91(1):34-38
pubmed: 27362704
Sci Transl Med. 2016 Sep 21;8(357):357ra123
pubmed: 27655849
Sci Immunol. 2019 May 10;4(35):
pubmed: 31076527
Curr Top Microbiol Immunol. 2014;377:95-109
pubmed: 23918170
Immunohorizons. 2020 Oct 16;4(10):634-647
pubmed: 33067399
Cytometry A. 2015 Nov;87(11):986-8
pubmed: 26228006
Cytometry A. 2019 Sep;95(9):946-951
pubmed: 31334918
J Virol. 2019 Mar 21;93(7):
pubmed: 30700608